Advertisement
U.S. markets open in 4 hours 46 minutes
  • S&P Futures

    5,305.00
    -3.25 (-0.06%)
     
  • Dow Futures

    40,130.00
    -14.00 (-0.03%)
     
  • Nasdaq Futures

    18,490.50
    -13.25 (-0.07%)
     
  • Russell 2000 Futures

    2,134.00
    -4.40 (-0.21%)
     
  • Crude Oil

    81.80
    +0.45 (+0.55%)
     
  • Gold

    2,214.60
    +1.90 (+0.09%)
     
  • Silver

    24.55
    -0.21 (-0.84%)
     
  • EUR/USD

    1.0794
    -0.0035 (-0.32%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.96
    +0.18 (+1.41%)
     
  • GBP/USD

    1.2609
    -0.0029 (-0.23%)
     
  • USD/JPY

    151.3610
    +0.1150 (+0.08%)
     
  • Bitcoin USD

    70,658.84
    +901.91 (+1.29%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,953.41
    +21.43 (+0.27%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

SHAREHOLDER ALERT: DIDI COIN CRMD: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / July 23, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Didi Global Inc. F/K/A Xiaoju Kuaizhi Inc. (NYSE:DIDI)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/didi-global-inc-f-k-a-xiaoju-kuaizhi-inc-loss-submission-form?prid=17935&wire=1
Lead Plaintiff Deadline: September 7, 2021
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired DiDi: (a) American Depositary Shares pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's June 2021 initial public offering; and/or (b) securities between June 30, 2021 and July 2, 2021, inclusive.

Allegations against DIDI include that: (1) DiDi's apps did not comply with applicable laws and regulations governing privacy protection and the collection of personal information; (2) as a result, the Company was reasonably likely to incur scrutiny from the Cyberspace Administration of China; (3) the CAC had already warned DiDi to delay its IPO to conduct a self-examination of its network security; (4) as a result of the foregoing, DiDi's apps were reasonably likely to be taken down from app stores in China, which would have an adverse effect on its financial results and operations; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Coinbase Global, Inc. (NASDAQ:COIN)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/coinbase-global-inc-loss-submission-form?prid=17935&wire=1
Lead Plaintiff Deadline: September 20, 2021
This lawsuit is on behalf of all persons and entities that purchased or otherwise acquired Coinbase Class A common stock pursuant and/or traceable to the Company's registration statement and prospectus for the resale of up to 114,850,769 shares of its Class A common stock, whereby Coinbase began trading as a public company on or around April 14, 2021.

Allegations against COIN include that: (1) the Company required a sizeable cash injection; (2) the Company's platform was susceptible to service-level disruptions, which were increasingly likely to occur as the Company scaled its services to a larger user base; and (3) as a result of the foregoing Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

CorMedix Inc. (NASDAQ:CRMD)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/cormedix-inc-loss-submission-form?prid=17935&wire=1
Lead Plaintiff Deadline: September 20, 2021
Class Period: July 8, 2020 - May 13, 2021

Allegations against CRMD include that: (i) deficiencies existed with respect to DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration ("FDA") was unlikely to approve the DefenCath new drug application ("NDA") for catheter-related bloodstream infections ("CRBSIs") in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong



View source version on accesswire.com:
https://www.accesswire.com/656903/SHAREHOLDER-ALERT-DIDI-COIN-CRMD-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines

Advertisement